Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T13:41:52.844Z.
Calculation as of: 2026-10-06T13:41:52.844Z.
Quote observation: 2026-10-06T13:40:04.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 77dbea8aa1c4b6afac8bad226ab17e7d6a7ad6f552ac01c17f7c344859946cda
PE RATIO
N/A
Caribou Biosciences, Inc.
Market Cap
$118.52M
PE Ratio
N/A
| NAME | MARKET CAP | PE RATIO |
|---|---|---|
| Caribou Biosciences, Inc. (CRBU) | $118.52M | N/A |
| BGM Group Ltd. (BGM)vs › | $111.78M | N/A |
| Genelux Corporation (GNLX)vs › | $117.03M | N/A |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $120.80M | N/A |
| Foghorn Therapeutics Inc. (FHTX)vs › | $116.84M | N/A |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $115.66M | N/A |
| LENZ Therapeutics, Inc. (LENZ)vs › | $114.76M | N/A |
| TuHURA Biosciences, Inc. (HURA)vs › | $119.09M | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $114.47M | N/A |
| Lucid Diagnostics Inc. (LUCD)vs › | $111.89M | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$1.20
Forward EPS (Est.)
$-0.95
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
